Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism
In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism.
Featured Articles:
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
Does IPSS-R down-staging before transplantation improve the prognosis of patients with Myelodysplastic Neoplasms?
Increased risk of venous thromboembolism [or VTE] in young…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.